Free Newsletter
BiondVax releases promising Ph2 universal flu vax results
BiondVax Pharmaceuticals has completed its first Phase II trial of Multimeric-001, its universal flu vaccine, and the results have spurred the company to begin planning its next test of the vaccine. The 200-participant study hit its primary and secondary endpoints, with good immunogenicity and safety data, including statistically significant antibody and cell-mediated immune responses.
"We have confirmed, in what is to our knowledge the first Phase II study of a universal influenza vaccine ever conducted in the world, that the Multimeric-001 vaccine is not only safe and immunogenic on its own, but it also has the potential to enhance the performance of traditional strain-dependant flu vaccines," Ron Babecoff, BiondVax's CEO, said in a release.
The Israeli company also stated that Multimeric-001, which was given in two doses during the trial, enhanced a traditional flu vaccine's performance. BiondVax's next trial of the vaccine is planned for the fourth quarter of this year and will evaluate the effects of the shot in elderly patients.
- check out the BiondVax release
- here's more from Reuters
Related Articles:
BiondVax looks to make mark in universal flu vax space
Fauci outlines R&D challenges to universal flu vaccine
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: